Research Paper Volume 16, Issue 8 pp 6868—6882

lincRNA00907 promotes NASH progression by targeting miRNA-942-5p/TAOK1

class="figure-viewer-img"

Figure 4. Knockdown of linc00907 alleviates NASH symptoms in HFHC diet mouse model. (A) Linc00907 knockdown results in lower body and liver weights, with a reduced liver/body weight ratio; (B) linc00907 knockdown leads to a reduction in serum ALT levels in mice; (C) linc00907 knockdown leads to a reduction in serum AST levels in mice; (D) mice in the knockdown group displayed lower blood glucose levels; (E) the OGTT confirmed higher glucose tolerance in linc00907 knockdown mice; (F) total triglyceride and total cholesterol levels in liver were lower in the knockdown group; (G) TG and TC levels in blood were lower in the knockdown group; (H) the serum phospholipid levels were also lower in the knockdown group; (I) H&E and Oil Red O staining of liver tissues; (J) α-SMA, Masson, COL1A1 and FASN staining of liver sections.